Aktualności
RAPS: FDA Guidance Aims to Clarify Development of Medical Countermeasures
28.08.2014
A new final guidance document issued by the US Food and Drug Administration (FDA) aims to make it easier to develop in vitro diagnostic devices (IVDs) intended to act as microbiological or medical
...
EMA: Recommendations for the implementation of the exemptions to the labelling and package-leaflet obligations in the centralised procedure
21.08.2014
This document aims to present the principles for the handling of the exemptions to the labelling and package leaflet obligations. ...
EMA: European Medicines Agency pre-authorisation procedural advice for users of the centralised procedure
21.08.2014
This guidance document addresses a number of questions which users of the centralised procedure may have. It provides an overview of the European Medicines Agency’s position on issues, which are
...
FDA: Clinical Pharmacology Labeling for Human Prescription Drug and Biological Products—Considerations, Content, and Format - draft guidance
21.08.2014
This guidance is intended to assist applicants in preparing the Clinical Pharmacology section of product labeling to meet regulatory requirements and ensure appropriate consistency in the format
...
FDA: Guidance for industry: Immunogenicity Assessment for Therapeutic Protein Product
21.08.2014
This guidance is intended to assist manufacturers and clinical investigators involved in the development of therapeutic protein products for human use. In this document, FDA outlines and
...
RAPS: Are New Policies Needed to Help Regulate Generic Drugs? FDA Wants to Know
21.08.2014
US drug regulators are getting ready to take a close look at the regulation of generic drugs, including new policies recently proposed by the US Food and Drug Administration (FDA) and areas that
...
EMA: Checking process of mock-ups and specimens of outer / immediate labelling and package leaflets of human medicinal products in the centralised procedure
14.08.2014
Since February 2007 the European Medicines Agency (EMA) has been operating an extensive checking process of the marketing-authorisation holder’s (MAH) printed packaging materials for outer and
...
FDA: Upper Facial Lines: Developing Botulinum Toxin Drug Products
14.08.2014
The purpose of this guidance is to assist sponsors in the clinical development of therapeutic biological products, specifically botulinum toxins, for the temporary improvement in the appearance of
...
EMA: EMA publishes Document on the Validation of analytical Methods
14.08.2014
The European Medicines Agency (EMA) published the concept paper \"Transferring quality control methods validated in collaborative trials to a product/laboratory specific context\". To accept a
...
GMP: Serious GMP Violations found at Chinese API Manufacturer - Basic GMP principles not followed
14.08.2014
On 7 July 2014 the US FDA has issued a Warning Letter for Zhejiang Jiuzhou Pharmaceutical Co., Ltd. located in Taizhou, Zhejiang Province in China. The company is a producer of APIs and failed to
...
